Analytical Data
-
基因名
CHRNa9
- Application
-
别名
CHRNa9；NACHRA9；Neuronal acetylcholine receptor subunit alpha-9
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q9UGM1
-
表达区间
1-479aa
-
氨基酸序列
MNWSHSCISFCWIYFAASRLRAAETADGKYAQKLFNDLFEDYSNALRPVEDTDKVLNVTLQITLSQIKDMDERNQILTAYLWIRQIWHDAYLTWDRDQYDGLDSIRIPSDLVWRPDIVLYNKADDESSEPVNTNVVLRYDGLITWDAPAITKSSCVVDVTYFPFDNQQCNLTFGSWTYNGNQVDIFNALDSGDLSDFIEDVEWEVHGMPAVKNVISYGCCSEPYPDVTFTLLLKRRSSFYIVNLLIPCVLISFLAPLSFYLPAASGEKVSLGVTILLAMTVFQLMVAEIMPASENVPLIGKYYIATMALITASTALTIMVMNIHFCGAEARPVPHWARVVILKYMSRVLFVYDVGESCLSPHHSRERDHLTKVYSKLPESNLKAARNKDLSRKKDMNKRLKNDLGCQGKNPQEAESYCAQYKVLTRNIEYIAKCLKDHKATNSKGSEWKKVAKVIDRFFMWIFFIMVFVMTILIIARAD
-
分子量
54.8 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The research on recombinant CHRNA9 protein has gained significant attention due to its crucial role in the physiology of the nervous system and its potential implications in various neurological disorders. CHRNA9 encodes the alpha-9 nicotinic acetylcholine receptor (nAChR), which is primarily expressed in cochlear hair cells and certain neurons, playing a vital role in auditory processing and cholinergic signaling. Dysregulation of CHRNA9 expression and function has been linked to several conditions, including auditory nerve damage and cancer, highlighting its importance in both sensory biology and pathophysiology. Additionally, the CHRNA9 protein is a promising target for developing therapeutic interventions aimed at chronic pain and neurodegenerative diseases. Recombinant CHRNA9 protein studies involve the expression and purification of this receptor to investigate its functional properties, pharmacological profiles, and interactions with various ligands and drugs. Understanding the structural and biochemical characteristics of the CHRNA9 receptor through recombinant technologies can pave the way for novel strategies to modulate its activity, potentially leading to innovative treatments for auditory and neurological disorders. As research progresses, the elucidation of the mechanisms underlying CHRNA9’s function and regulation holds promise for unlocking new avenues in both basic and applied biomedical sciences.
